📣 VC round data is live. Check it out!
- Public Comps
- BillionToOne
BillionToOne Valuation Multiples
Discover revenue and EBITDA valuation multiples for BillionToOne and similar public comparables like Jiangsu Yuyue Medical, LivaNova, iRhythm Holdings, Merit Medical Systems and more.
BillionToOne Overview
About BillionToOne
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
Founded
2016
HQ

Employees
N/A
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialBillionToOne Financials
BillionToOne reported last 12-month revenue of $363M and EBITDA of $56M.
In the same LTM period, BillionToOne generated $254M in gross profit, $56M in EBITDA, and $21M in net income.
Revenue (LTM)
BillionToOne P&L
In the most recent fiscal year, BillionToOne reported revenue of $305M and EBITDA of $37M.
BillionToOne is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 12%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
BillionToOne Stock Performance
BillionToOne has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
BillionToOne's stock price is $85.92.
BillionToOne share price increased by 14.3% in the last 30 days.
BillionToOne has an EPS (earnings per share) of $0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -0.3% | 14.3% | 12.6% | — | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBillionToOne Valuation Multiples
BillionToOne trades at 9.8x EV/Revenue multiple, and 63.0x EV/EBITDA.
EV / Revenue (LTM)
BillionToOne Financial Valuation Multiples
As of May 23, 2026, BillionToOne has market cap of $4B and EV of $4B.
BillionToOne has a P/E ratio of 190.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BillionToOne Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


BillionToOne Margins & Growth Rates
BillionToOne grew revenue by 49% and EBITDA by 131% in the last fiscal year.
In the most recent fiscal year, BillionToOne reported gross margin of 68%, EBITDA margin of 12%, and net margin of 2%.
BillionToOne Margins
BillionToOne Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
BillionToOne Operational KPIs
BillionToOne's Rule of 40 is 68% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BillionToOne's Rule of X is 141% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
BillionToOne Competitors
BillionToOne competitors include Jiangsu Yuyue Medical, LivaNova, iRhythm Holdings, Merit Medical Systems, Ottobock, Envista Holdings, Twist Bioscience, Rigaku, Medacta Group and Veracyte.
Most BillionToOne public comparables operate across Diagnostics & Genomics, Medical Devices, Life Sciences Tools, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.3x | 3.2x | 13.5x | 16.4x | |||
| 2.8x | 2.7x | 12.2x | 11.7x | |||
| 5.4x | 5.0x | 58.2x | 47.2x | |||
| 2.7x | 2.7x | 11.0x | 10.7x | |||
| 2.9x | 2.7x | 15.6x | 10.9x | |||
| 1.6x | 1.6x | 11.6x | 11.2x | |||
| 9.8x | 8.8x | (78.7x) | (97.1x) | |||
| 6.5x | 6.3x | 28.0x | 26.5x | |||
This data is available for Pro users. Sign up to see all BillionToOne competitors and their valuation data. Start Free Trial | ||||||
BillionToOne Funding History
Before going public, BillionToOne raised $391M in total equity funding, across 7 rounds.
Last private valuation of BillionToOne was $1B, after raising $130M in June 2024 from Adams Street Partners, Baillie Gifford, Civilization Ventures, and 6 other investors.
BillionToOne Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BillionToOne
| When was BillionToOne founded? | BillionToOne was founded in 2016. |
| Where is BillionToOne headquartered? | BillionToOne is headquartered in United States. |
| Is BillionToOne publicly listed? | Yes, BillionToOne is a public company listed on Nasdaq. |
| What is the stock symbol of BillionToOne? | BillionToOne trades under BLLN ticker. |
| When did BillionToOne go public? | BillionToOne went public in 2025. |
| Who are competitors of BillionToOne? | BillionToOne main competitors include Jiangsu Yuyue Medical, LivaNova, iRhythm Holdings, Merit Medical Systems, Ottobock, Envista Holdings, Twist Bioscience, Rigaku, Medacta Group, Veracyte. |
| What is the current market cap of BillionToOne? | BillionToOne's current market cap is $4B. |
| What is the current revenue of BillionToOne? | BillionToOne's last 12 months revenue is $363M. |
| What is the current revenue growth of BillionToOne? | BillionToOne revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of BillionToOne? | Current revenue multiple of BillionToOne is 9.8x. |
| Is BillionToOne profitable? | Yes, BillionToOne is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BillionToOne? | BillionToOne's last 12 months EBITDA is $56M. |
| What is BillionToOne's EBITDA margin? | BillionToOne's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of BillionToOne? | Current EBITDA multiple of BillionToOne is 63.0x. |
| What is the current FCF of BillionToOne? | BillionToOne's last 12 months FCF is $24M. |
| What is BillionToOne's FCF margin? | BillionToOne's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of BillionToOne? | Current FCF multiple of BillionToOne is 151.2x. |
| How many companies BillionToOne has acquired to date? | BillionToOne hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies BillionToOne has invested to date? | BillionToOne hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to BillionToOne
Lists including BillionToOne
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.